CBD of Denver Targets European Market With Greek Growth
The firm plans to increase production capacity to capture a share of the European CBD market, projected to hit USD 6 billion by 2033.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do you support the continued expansion and commercial growth of the European cannabinoid market?
CBD of Denver has detailed strategic plans to scale its BioCannabis platform operations in Nea Apollonia, Greece. The company aims to expand its processing capacity to capitalize on the growing European cannabidiol market.
Why it matters
The strategy highlights the industry push to capture higher margins through vertical integration as the European CBD market moves toward an estimated USD 6 billion valuation by 2033.
The firm currently operates 7,200 square meters of total facilities, including 5,000 square meters dedicated to greenhouse cultivation. This infrastructure supports a baseline production capacity of 3,000 kilograms of dried flower per year.
The players
CBD of Denver
A Denver-based firm focused on the cultivation and extraction of cannabinoid products for the European market.
The details
The facility in Greece utilizes an integrated model that combines cultivation, processing, and extraction within a single site. By streamlining these steps, the company expects to move beyond raw output toward producing higher-value cannabinoid derivatives. This consolidation of the supply chain is intended to improve operational efficiency compared to fragmented multi-site processing workflows.
Timeline
2025: The European cannabidiol market reached a value of USD 2.3 billion.
October 29, 2026: CBD of Denver outlined its latest strategic priorities.
2033: The European cannabidiol market is projected to reach USD 6.0 billion.
2034: Industry projections indicate potential growth for the global CBG market.
The Tech Race
CBD of Denver is positioning its Greek facilities to capture share in a market dominated by hemp-derived products, which held 78% of the European sector in 2025. The company is betting on vertical integration to compete against the projected 12.7% compound annual growth rate in European CBD value through 2033.
Increased processing capacity at the Greek site is expected to eventually provide European customers with a broader range of value-added cannabinoid products. Availability timelines for these new formulations remain unannounced as the company continues facility development.
The takeaway
The company is betting that vertical integration is the path to capturing value in a market growing at an estimated 12.7% annually. Watch for updates on the facility’s processing efficiency benchmarks, which will indicate how effectively the firm is scaling its production of value-added products.
Further reading
For more on the latest research and industrial scaling in the sector, see Biotech.
Source note: This article includes information reported by Simcoe Reformer.
Live Poll
Do you support the continued expansion and commercial growth of the European cannabinoid market?
